Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan G Duda

Showing results (21-30 of 261) with videos related to

Pageof 27
Sort By:
Surgical Oncology|September 18, 2025
Thirty-Five years of globalizing surgical oncology knowledge: A look into the future - IASGO Cairo 2024Dan G Duda, Mohamed Abdel Wahab, Kyoichi Takaori
Immunotherapy|February 12, 2016
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinomaTai Hato, Andrew X Zhu, Dan G Duda
Cancer Journal (Sudbury, Mass.)|July 30, 2015
From the Guest Editors: Role of Tumor Microenvironment in Tumor Progression and Treatment Response: A 30 Years' JourneyRakesh K Jain, Dai Fukumura, Dan G Duda
JAMA Oncology|October 22, 2020
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A ReviewMatthias Pinter, Rakesh K Jain, Dan G Duda
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?Dan G Duda, Marek Ancukiewicz, Rakesh K Jain
Cancer Research|May 3, 2019
Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System?Zohreh Amoozgar, Rakesh K Jain, Dan G Duda
Angiogenesis|April 1, 2017
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Rakesh R Ramjiawan, Arjan W Griffioen, Dan G Duda
Disease Models & Mechanisms|March 5, 2009
Visualizing anti-tumor immune responses in vivoJean Y Perentes, Dan G Duda, Rakesh K Jain
Circulation Research|August 28, 2020
Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55α Complex the Answer?John D Martin, Dan G Duda, Rakesh K Jain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2007
Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancersDan G Duda, Rakesh K Jain, Christopher G Willett
Pageof 27

Showing results (21-30 of 261) with videos related to

Sort By:
Pageof 27
Surgical Oncology|September 18, 2025
Thirty-Five years of globalizing surgical oncology knowledge: A look into the future - IASGO Cairo 2024Dan G Duda, Mohamed Abdel Wahab, Kyoichi Takaori
Immunotherapy|February 12, 2016
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinomaTai Hato, Andrew X Zhu, Dan G Duda
Cancer Journal (Sudbury, Mass.)|July 30, 2015
From the Guest Editors: Role of Tumor Microenvironment in Tumor Progression and Treatment Response: A 30 Years' JourneyRakesh K Jain, Dai Fukumura, Dan G Duda
JAMA Oncology|October 22, 2020
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A ReviewMatthias Pinter, Rakesh K Jain, Dan G Duda
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?Dan G Duda, Marek Ancukiewicz, Rakesh K Jain
Cancer Research|May 3, 2019
Role of Apelin in Glioblastoma Vascularization and Invasion after Anti-VEGF Therapy: What Is the Impact on the Immune System?Zohreh Amoozgar, Rakesh K Jain, Dan G Duda
Angiogenesis|April 1, 2017
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Rakesh R Ramjiawan, Arjan W Griffioen, Dan G Duda
Disease Models & Mechanisms|March 5, 2009
Visualizing anti-tumor immune responses in vivoJean Y Perentes, Dan G Duda, Rakesh K Jain
Circulation Research|August 28, 2020
Going Beyond VEGF Pathway Inhibition for Antiangiogenic Cancer Therapy: Is Inhibition of the PP2A/B55α Complex the Answer?John D Martin, Dan G Duda, Rakesh K Jain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2007
Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancersDan G Duda, Rakesh K Jain, Christopher G Willett
Pageof 27